Nov
16
2020
Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business Highlights
Participants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinson’s diseaseDebuted as publicly traded …